Transcenta and EirGenix Announce Major Biomanufacturing Partnership

PRINCETON, N.J. and HANGZHOU, China – December 28, 2025 – In a strategic move poised to reshape the production of complex biologic medicines, Transcenta Therapeutics today announced a significant collaboration with EirGenix Inc. The agreement grants EirGenix, a leading Taiwanese biopharmaceutical development and manufacturing company, a non-exclusive license to Transcenta's cutting-edge continuous bioprocessing platform, aiming to make high-quality biologic therapies more affordable and accessible to patients worldwide.

The partnership centers on Transcenta's proprietary Highly Intensified Continuous Bioprocessing (HiCB) platform. This advanced manufacturing technology represents a paradigm shift from traditional methods, promising to streamline production, enhance product quality, and dramatically lower costs.

Revolutionizing Biologic Production

For decades, the biopharmaceutical industry has relied on conventional fed-batch manufacturing, a process where cells are grown in large bioreactors for a set period to produce a single, large batch of a drug. While effective, this method is often time-consuming, requires massive facility footprints, and can lead to variability between batches.

Transcenta's HiCB platform disrupts this model by implementing a continuous, integrated system. It combines highly productive continuous perfusion—where cell cultures are constantly fed fresh nutrients and waste is removed—with a hybrid continuous purification process. This creates a steady, uninterrupted flow of production that operates on a smaller scale but runs for extended periods, yielding a comparable or even greater amount of product over time.

The key advantages of this platform are substantial. Continuous manufacturing allows for greater process efficiency and tighter control over production parameters, which leads to improved product consistency and quality. Perhaps most critically, by intensifying the process and reducing the scale of equipment needed, the HiCB platform can significantly reduce the cost of goods sold (COGS). This cost reduction is a crucial step toward expanding global patient access to innovative but often expensive antibody-based therapeutics.

A Strategic and Financial Win-Win

Under the terms of the agreement, Transcenta will provide EirGenix with a comprehensive package that includes not only the license to use the HiCB technology but also detailed process documentation, essential know-how, and regulatory support to ensure successful implementation. In return, Transcenta is set to receive a substantial upfront payment, future milestone payments tied to specific achievements, and ongoing royalties from the commercial use of the licensed technologies.

This deal structure reflects the long-term value both companies anticipate generating. For EirGenix, a globally recognized Contract Development and Manufacturing Organization (CDMO), the adoption of the HiCB platform is a powerful strategic enhancement. The company will apply the technology to its own biologics development programs while also offering it as a state-of-the-art service to its global CDMO clients who are increasingly seeking intensified and continuous manufacturing solutions.

By integrating HiCB, EirGenix can position itself at the forefront of manufacturing innovation, attracting partners who want to develop biologics more efficiently and sustainably. This expands the reach and impact of Transcenta's technology far beyond its own pipeline.

A Shared Vision for Global Health

The collaboration is underpinned by a mutual goal to transform the biopharmaceutical landscape for the better. Leaders from both companies emphasized the synergistic nature of the partnership.

"We are pleased to share our HiCB platform, a result of Transcenta’s leadership in highly intensified continuous bioprocessing, with partners who share our vision of transforming biologics manufacturing," said Dr. Xueming Qian, Chairman and CEO of Transcenta. He noted that by enabling other companies to adopt the platform, the industry can collectively advance the affordability of and global access to innovative medicines. "The proceeds from this and future collaborations will be reinvested to further strengthen our technology platform and advance our R&D pipeline to deliver next-generation, best-in-class therapeutics."

Dr. L.-C. Liu, Chairman and President of EirGenix, echoed this sentiment, calling the deal a "win–win partnership that combines Transcenta’s innovation in continuous biomanufacturing and EirGenix’s proven bioprocessing and CDMO expertise."

"Together, we aim to redefine how biologics are made—more efficiently, sustainably, and at lower cost—to reach more patients worldwide," Dr. Liu stated.

Profiles in Innovation

This partnership brings together two highly capable players in the biopharmaceutical sector. Transcenta Therapeutics is a clinical-stage company with a global footprint and fully integrated capabilities, from initial discovery to late-stage manufacturing. With R&D and clinical centers in China, the U.S., and Europe, the company is advancing a diverse pipeline of more than a dozen novel antibody-based therapies for cancer and other serious conditions like bone and kidney disorders.

EirGenix Inc. stands as Taiwan’s largest biologics CDMO, providing comprehensive services that span the entire development and manufacturing lifecycle. With a strong reputation for quality and regulatory compliance, EirGenix supports global partners in bringing their products to market while also developing its own portfolio of biosimilars and antibody-drug conjugates (ADCs). The collaboration with Transcenta allows EirGenix to add another powerful tool to its advanced manufacturing arsenal, reinforcing its commitment to making high-quality biologics accessible across the globe.